The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

Phase I-II Trial of the Anti CD74 Monoclonal Antibody-Milatuzumab as a Single Agent in Refractory Chronic Lymphocytic Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00868478
• Other study ID #: KMC-07-0080-CTIL
• Status: Recruiting
• Phase: Phase 1/Phase 2
• First received: March 24, 2009
• Last updated: June 1, 2010
• Start date: April 2009
• Est. completion date: April 2012

Study information

• Verified date: September 2009
• Source: Kaplan Medical Center
• Contact: Michal Z Haran, MD
• Phone: 972-8-9441-211
• Email: haran[@]clalit.org.il
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Milatuzumab is effective in patients with refractory chronic lymphocytic leukemia, and also to find out in which range of doses is a response seen.

Description:

The aim of this study is to determine whether the anti-CD74 monoclonal antibody Milatuzumab provides benefit to subjects with CLL in advanced stage or progressive disease. The primary objectives of this study are to assess response rate to the agent, as well as the safety in CLL, using different doses: Overall response (OR), complete response (CR) and partial response (PR) will be determinate according to the NCI criteria.

The secondary objectives are to determine: duration of response, time to progression, overall survival, and the range of doses in which efficacy is seen and MTD not reached.

This study will be done in parallel with other phase I-II studies conducted by Immunomedics.

The study design will take into account that the high levels of circulating CD74expressing cells in CLL may affect both the acute (although probably not long term) toxicity and the efficacy of the study medication. This could translate to a different MTD and a different cumulative dose of Milatuzumab, needed to achieve response.(either a higher dose or longer treatment period.).

The study will be divided into two treatment phases. In the first phase we aim to address whether the dose of 120 mg/m2 is effective in CLL, and also if it is safe. In the second phase we will assess the safety and possible efficacy of higher doses, in those patients that did not achieve a significant response in the first phase. This will be done by gradual dose escalations, not to exceed 600 mg, or the MTD reached in other studies.

In addition, the study will aim at gaining further understanding of the effect of Milatuzumab on the biological in-vitro function of CLL cells.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: April 2012
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• B-CLL confirmed according to NCI criteria

• CLL relapsed or refractory to prior antineoplastic therapy

• Signs of progressive disease; at least one:

• B symptoms

• lymphocyte doubling time of < 6 months

• symptomatic lymphadenopathy or splenomegaly

• cytopenias due to bone marrow failure)

• Age > 18 years, and less then 80

• Serum ALAT, ASAT, bilirubin, creatinine < 2x upper limit of normal

• Life expectancy > 6 months

• Patient's written informed consent

Exclusion Criteria:

• Active bacterial or viral infection

• Hypersensitivity to humanized monoclonal antibodies

• Concurrent antineoplastic treatment for CLL or other malignant disease

• Absolute neutrophil count < 1.5 K/

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Drug:
• Milatuzumab
Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.

Locations

Country	Name	City	State
Israel	Kaplan Medical Center	Rehovot

Sponsors (2)

Lead Sponsor	Collaborator
Kaplan Medical Center	Immunomedics, Inc.

Country where clinical trial is conducted

Israel, 

References & Publications (1)

Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N, Leng L, Goldenberg DM, Shvidel L, Berrebi A, Bucala R, Shachar I. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13408-13. Epub 2007 Aug 8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response to treatment		12 weeks, 24 weeks	No